ImageneBio (NASDAQ:IMA) Stock Price Down 8.5% – Here’s Why

ImageneBio, Inc. (NASDAQ:IMA) shares were down 8.5% on Monday . The company traded as low as $4.55 and last traded at $4.55. Approximately 13,355 shares changed hands during trading, a decline of 68% from the average daily volume of 41,319 shares. The stock had previously closed at $4.97.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of ImageneBio from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, ImageneBio presently has a consensus rating of “Hold” and an average price target of $26.50.

ImageneBio Price Performance

The business’s 50 day simple moving average is $6.27 and its 200 day simple moving average is $6.95. The company has a market capitalization of $48.46 million, a PE ratio of -0.56 and a beta of 0.55.

ImageneBio (NASDAQ:IMA) last issued its earnings results on Tuesday, March 10th. The company reported $0.34 EPS for the quarter. As a group, analysts anticipate that ImageneBio, Inc. will post -0.91 EPS for the current year.

Hedge Funds Weigh In On ImageneBio

Institutional investors have recently bought and sold shares of the company. Barclays PLC raised its stake in ImageneBio by 170.8% during the fourth quarter. Barclays PLC now owns 10,797 shares of the company’s stock worth $74,000 after purchasing an additional 6,810 shares during the period. Goldman Sachs Group Inc. purchased a new position in ImageneBio during the fourth quarter worth about $76,000. Millennium Management LLC purchased a new position in ImageneBio during the fourth quarter worth about $79,000. Bridgeway Capital Management LLC purchased a new position in ImageneBio during the third quarter worth about $104,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of ImageneBio in the 3rd quarter valued at approximately $106,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.